MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial - Scorecard - MDSpire

MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial

  • By

  • Martin Wermke

  • Sebastian Ochsenreither

  • Dirk Jaeger

  • Heiko Becker

  • Annalen Bleckmann

  • Farastuk Bozorgmehr

  • Manik Chatterjee

  • Stefanie Groepper

  • Mathias Haenel

  • Judith S. Hecker

  • Max-Felix Häring

  • Daniel Heudobler

  • Norbert Hilf

  • Martin Hofmann

  • Meike Hutt

  • Andrea Mayer-Mokler

  • Sarah Missel

  • Manuel Ruh

  • Heiko Schuster

  • Olga Veremchuk

  • Moritz Kleemiss

  • Stefan Knop

  • Simon Laban

  • Martin Sebastian

  • Silvia Spoerl

  • Cedrik Michael Britten

  • Carsten Reinhardt

  • May 31, 2026

  • 0 min

Share

Clinical Scorecard: Targeting MAGE-A4 and MAGE-A8 with TCR-based Bispecific T Cell Engagers in Recurrent or Refractory Solid Tumors: Results from a Phase 1 Study

At a Glance

CategoryDetail
Condition
Key MechanismsTCR-based T cell engagers targeting intracellular antigens presented on HLA class I molecules.
Target Population
Care Setting

Key Highlights

  • IMA401 targets MAGE-A4 and MAGE-A8 peptides with high specificity.
  • Combination with pembrolizumab evaluated for enhanced antitumor activity.

Guideline-Based Recommendations

Diagnosis

    Management

    • Evaluate IMA401 as monotherapy and in combination with pembrolizumab.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        IMA401 targets MAGE-A4/8 with a favorable safety profile.

        Clinical Best Practices

        • Utilize pharmacokinetic parameters to guide dosing.

        Related Resources & Content

        Original Source(s)

        MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial

        • by Martin Wermke, Sebastian Ochsenreither, Dirk Jaeger, Heiko Becker, Annalen Bleckmann, Farastuk Bozorgmehr, Manik Chatterjee, Stefanie Groepper, Mathias Haenel, Judith S. Hecker, Max-Felix Häring, Daniel Heudobler, Norbert Hilf, Martin Hofmann, Meike Hutt, Andrea Mayer-Mokler, Sarah Missel, Manuel Ruh, Heiko Schuster, Olga Veremchuk, Moritz Kleemiss, Stefan Knop, Simon Laban, Martin Sebastian, Silvia Spoerl, Cedrik Michael Britten, Carsten Reinhardt

        • May 31, 2026

        Related Content

        From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer

        Data requirements of an informative, directive, and preventive mobile health application for gastric cancer

        Artificial intelligence for optimization of immunotherapy: current applications and transformative potential